Lucid Diagnostics Inc.LUCDEarnings & Financial Report
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics firm focused on non-invasive screening tests for upper gastrointestinal diseases, including early detection of esophageal cancer and pre-cancerous lesions. It mainly serves healthcare providers and clinical partners across the United States, targeting at-risk patient populations.
Revenue
$976.0K
Gross Profit
N/A
Operating Profit
$-11.2M
Net Profit
$-11.0M
Gross Margin
N/A
Operating Margin
-1146.7%
Net Margin
-1127.6%
YoY Growth
513.8%
EPS
$-0.23
Lucid Diagnostics Inc. Q2 FY2024 Financial Summary
Lucid Diagnostics Inc. reported revenue of $976.0K (up 513.8% YoY) for Q2 FY2024, with a net profit of $-11.0M (up 3.3% YoY) (-1127.6% margin).
Key Financial Metrics
| Total Revenue | $976.0K |
|---|---|
| Net Profit | $-11.0M |
| Gross Margin | N/A |
| Operating Margin | -1146.7% |
| Report Period | Q2 FY2024 |
Lucid Diagnostics Inc. Annual Revenue by Year
Lucid Diagnostics Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $4.3M).
| Year | Annual Revenue |
|---|---|
| 2024 | $4.3M |
| 2023 | $2.4M |
Lucid Diagnostics Inc. Quarterly Revenue & Net Profit History
Lucid Diagnostics Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $1.2M | +3.3% | $-10.4M | -858.5% |
| Q2 FY2025 | $1.2M | +19.2% | $-4.4M | -381.7% |
| Q1 FY2025 | $828.0K | -17.3% | $-26.9M | -3249.8% |
| Q4 FY2024 | $1.2M | +15.1% | $-11.5M | -964.2% |
| Q3 FY2024 | $1.2M | +49.7% | $-12.4M | -1055.5% |
| Q2 FY2024 | $976.0K | +513.8% | $-11.0M | -1127.6% |
| Q1 FY2024 | $1.0M | +124.4% | $-10.6M | -1060.1% |
| Q4 FY2023 | $1.0M | +828.6% | $-10.8M | -1041.3% |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $1.0M | $976000 | $1.2M | $1.2M | $828000 | $1.2M | $1.2M |
| YoY Growth | 828.6% | 124.4% | 513.8% | 49.7% | 15.1% | -17.3% | 19.2% | 3.3% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $27.3M | $32.0M | $34.1M | $22.6M | $30.7M | $32.8M | $38.7M | $53.2M |
| Liabilities | $29.6M | $20.2M | $18.1M | $16.3M | $25.3M | $38.2M | $30.8M | $27.4M |
| Equity | $-2.3M | $11.9M | $16.0M | $6.3M | $5.4M | $-5.4M | $7.9M | $25.8M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-10.0M | $-12.6M | $-11.5M | $-10.2M | $-9.9M | $-12.5M | $-10.5M | $-10.9M |